NYMOX PHARMACEUTICAL CORP (NYMXF)
Institutional ownership reported to the SEC as of Q2 2026, across 31 quarters.
1
Reporting holders
$4.2K
Reported value
0.0%
Held as options
+0
Holder change
Options share is the part of reported value carried in derivative lines rather than shares. A high figure means institutions are expressing a view on this security without owning much of it.
Holders
| Filer | Value | Shares | Their book | Held | Change |
|---|---|---|---|---|---|
| First Citizens Financial Corp | $4.2K | 35,100 | 0.00% | 25q | HELD |
Quarter by quarter
Coverage begins with the quarter ending 2018-12-31. Earlier filings exist only as occasional late amendments, too sparse to describe a market, so they are not shown.
| Quarter | Holders | Value | Shares | New | Added | Trimmed | Options |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 1 | $4.2K | 35,100 | 0 | 0 | 0 | 0.0% |
| Q1 2026 | 1 | $2.5K | 35,100 | 0 | 0 | 0 | 0.0% |
| Q4 2025 | 1 | $1.4K | 35,100 | 0 | 0 | 0 | 0.0% |
| Q3 2025 | 1 | $2.1K | 35,100 | 0 | 0 | 0 | 0.0% |
| Q2 2025 | 1 | $4.1K | 35,100 | 0 | 0 | 0 | 0.0% |
| Q1 2025 | 2 | $16.0K | 110,100 | 1 | 0 | 0 | 0.0% |
| Q4 2024 | 1 | $3.5K | 35,100 | 0 | 0 | 0 | 0.0% |
| Q3 2024 | 2 | $13.2K | 110,100 | 1 | 0 | 0 | 0.0% |
| Q2 2024 | 1 | $6.7K | 35,100 | 0 | 0 | 0 | 0.0% |
| Q1 2024 | 3 | $48.0K | 120,100 | 1 | 0 | 0 | 0.0% |
| Q4 2023 | 2 | $26.6K | 45,100 | 0 | 0 | 0 | 0.0% |
| Q3 2023 | 4 | $68.3K | 130,100 | 0 | 0 | 0 | 0.0% |
| Q2 2023 | 33 | $273.5K | 1,428,451 | 4 | 5 | 4 | 0.8% |
| Q1 2023 | 30 | $537.1K | 1,557,817 | 3 | 7 | 6 | 1.3% |
| Q4 2022 | 30 | $380.9K | 1,178,071 | 6 | 6 | 6 | 2.2% |
| Q3 2022 | 30 | $510.6K | 1,187,215 | 6 | 4 | 6 | 3.1% |
| Q2 2022 | 34 | $601.1K | 1,362,431 | 4 | 1 | 12 | 1.8% |
| Q1 2022 | 37 | $2.3M | 1,784,718 | 8 | 3 | 6 | 3.1% |
| Q4 2021 | 39 | $2.2M | 1,639,044 | 5 | 4 | 15 | 1.1% |
| Q3 2021 | 38 | $4.1M | 1,942,599 | 2 | 6 | 15 | 2.7% |
| Q2 2021 | 51 | $4.1M | 2,554,076 | 15 | 11 | 13 | 1.9% |
| Q1 2021 | 58 | $13.4M | 6,024,153 | 5 | 17 | 14 | 0.4% |
| Q4 2020 | 57 | $14.5M | 5,794,045 | 1 | 21 | 11 | 1.1% |
| Q3 2020 | 64 | $14.2M | 5,699,525 | 5 | 12 | 22 | 1.1% |
| Q2 2020 | 63 | $20.6M | 5,603,751 | 22 | 12 | 12 | 3.3% |
| Q1 2020 | 48 | $6.5M | 2,700,257 | 11 | 8 | 11 | 3.2% |
| Q4 2019 | 46 | $5.3M | 2,372,140 | 11 | 9 | 11 | 1.3% |
| Q3 2019 | 39 | $3.9M | 2,069,258 | 4 | 3 | 13 | 3.3% |
| Q2 2019 | 44 | $5.3M | 3,427,027 | 8 | 5 | 16 | 6.2% |
| Q1 2019 | 47 | $9.1M | 4,530,395 | 3 | 9 | 17 | 2.2% |
| Q4 2018 | 48 | $6.8M | 4,898,184 | 1 | 0 | 3 | 6.2% |